Free Trial
→ Ticker Revealed: Pre-IPO Access to 'Next Elon Musk' Company (From Banyan Hill Publishing) (Ad)tc pixel
LON:TCF

Theracryf Interim Earnings Report

GBX 0.22 0.00 (-0.89%)
As of 07:18 AM Eastern
ProfileEarnings History

Theracryf EPS Results

Actual EPS
-GBX 29
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Theracryf Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Theracryf Announcement Details

Quarter
Interim
Date
11/28/2024
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Theracryf Earnings Headlines

TheraCryf appoints new board member, issues options
May 2, 2025  |  uk.investing.comhttps://uk.investing.com/news/company-news/theracryf-appoints-new-board-member-issues-options-93CH-4058518
Theracryf Plc (TCF.L)
January 18, 2025  |  ca.finance.yahoo.comhttps://ca.finance.yahoo.com/quote/TCF.L/hiring-trends/
June 12: $100 Turns Into $100,000?
The SpaceX IPO is scheduled for June 12, and former tech executive Jeff Brown - who identified Bitcoin, Tesla, and Nvidia before major runs - says the window to get in early is closing fast. Brown is showing investors how to claim a stake in Elon Musk's company before it hits the public markets. Once the IPO happens, this pre-public opportunity disappears.tc pixel
June 5 at 1:00 AM  |  Brownstone Research (Ad)
Theracryf PLC Share Chat (TCF)
January 13, 2025  |  lse.co.ukhttps://www.lse.co.uk/ShareChat.html?ShareTicker=TCF&thread=D6EDFB9D-E83F-43D6-8E6C-4DBC80FD8FDF
See More Theracryf Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Theracryf? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Theracryf and other key companies, straight to your email.

About Theracryf

Theracryf (LON:TCF) is a biotechnology company developing new medicines for addiction and other disorders of the brain, areas of significant unmet medical need within central nervous system (CNS) disorders. The Group’s lead programme is a novel, best-in-class orexin-1 receptor antagonist being developed as a potential treatment for addiction, including binge eating, alcohol and other substance use disorders. The programme is heavily de-risked, demonstrates superior selectivity and high receptor occupancy, and is fully funded through to clinical readiness, with regulatory submissions targeted for 2026. TheraCryf also has a dopamine transporter (DAT) modulator programme addressing fatigue of brain origin, including fatigue associated with multiple sclerosis, chemotherapy and narcolepsy. The Group also has a legacy, grant-funded, oncology programme in glioblastoma with SFX-01. TheraCryf operates a capital-light, virtual development model advancing programmes to early clinical or proof-of-concept stage before partnering with larger pharmaceutical or biotechnology companies.

View Theracryf Profile
Earnings Tools